A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
NCT ID: NCT00811018
Last Updated: 2012-04-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1192 participants
INTERVENTIONAL
2003-03-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
NCT00795639
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
NCT00796510
A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
NCT01204853
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
NCT01210443
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
NCT00034307
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sitaxsentan
Sitaxsentan
Sitaxsentan
Sitaxsentan 100 mg tablets once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sitaxsentan
Sitaxsentan 100 mg tablets once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current diagnosis of WHO group 1 PAH with functional class 2, 3, or 4 symptoms.
Exclusion Criteria
* Has history of left sided heart disease or significant cardiac disease.
12 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Torrence, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Augusta, Georgia, United States
Pfizer Investigational Site
Decatur, Georgia, United States
Pfizer Investigational Site
Decatur, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Kansas City, Kansas, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Portland, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Rochester, Minnesota, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Galveston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Capital Federal, Buenos Aires, Argentina
Pfizer Investigational Site
Capital Federal, , Argentina
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
Chermside Q, Queensland, Australia
Pfizer Investigational Site
Melbourne, Victoria, Australia
Pfizer Investigational Site
Chermside, , Australia
Pfizer Investigational Site
Graz, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, , Brazil
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Clamart, , France
Pfizer Investigational Site
Grenoble, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Dresden, , Germany
Pfizer Investigational Site
Giessen, , Germany
Pfizer Investigational Site
Greifswald, , Germany
Pfizer Investigational Site
Hanover, , Germany
Pfizer Investigational Site
Heidelberg, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Regensburg, , Germany
Pfizer Investigational Site
Petah Tikva, , Israel
Pfizer Investigational Site
Tel-Hashomer, Ramat Gan, , Israel
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Monterrey, CP, Mexico
Pfizer Investigational Site
Tlalpan, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, N.l., Mexico
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Zabrze, , Poland
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Papworth Everard, Cambridgeshire, United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Newcastle, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FPH03
Identifier Type: -
Identifier Source: secondary_id
B1321007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.